A Phase II Multicenter Study of Gallium Nitrate in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
This study seeks to define the role of gallium nitrate in a specific population of patients
who are expected to have received prior therapy. Preliminary clinical studies have
suggested substantial evidence of antitumor activity in patients with relapsed or refractory
non-Hodgkin's Lymphoma treated with gallium nitrate.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration
|Genta||Berkeley Heights, New Jersey 07922|